A comparative study of visual function, QOL, and satisfaction in patients with BRVO or CRVO macular edema being treated with existing anti-VEGF agents, before and after switching to ranibizumab BS - A comparative study of visual function, QOL, and satisfaction in patients with RVO, before and after switching to ranibizumab BS

Start Date25 Jul 2024

Sponsor / Collaborator

Nippon Medical School Hospital

ChiCTR2300070096

/ SuspendedEarly Phase 1IIT

The Clinical Value of Contrast-Enhanced Ultrasonography in the Diagnosis and Treatment of Central Retinal Artery and Vein Occlusion

Start Date01 Apr 2023

Sponsor / Collaborator-

ChiCTR1900021193

/ SuspendedPhase 4IIT

Efficiency and safety of Conbercept intravitreal injection combined with posterior sub-tenon injection of triamcinolone acetonide in macular edema due to central retinal vein occlusion

Start Date01 Feb 2019

Sponsor / Collaborator

China-Japan Friendship Hospital

100 Clinical Results associated with Central retinal vein occlusion - ischemic

100 Translational Medicine associated with Central retinal vein occlusion - ischemic

0 Patents (Medical) associated with Central retinal vein occlusion - ischemic

392

Literatures (Medical) associated with Central retinal vein occlusion - ischemic

01 Jan 2025·Ophthalmology Retina

Retrospective Cohort Study of Sickle Cell Disease and Large Vessel Retinal Vascular Occlusion Risk in a National United States Database

Article

Author: Singh, Rishi P ; Talcott, Katherine E ; Kaufmann, Gabriel T ; Shukla, Priya ; Russell, Matthew

OBJECTIVETo determine if differences exist in the risk of developing large vessel retinal vascular occlusions in patients with sickle cell states.DESIGNRetrospective cohort study.PARTICIPANTSPatients with sickle cell disease (SCD) or trait evaluated by an ophthalmologist were compared with matched controls without SCD or sickle cell trait (SCT) also evaluated by an ophthalmologist.METHODSThis study used deidentified data from a national database (2006-2024), using International Classification of Diseases 10 codes to select for retinal vascular occlusions. Propensity score matching was performed with respect to age, sex, race, ethnicity, smoking, hypertension, diabetes, dyslipidemias, and obesity, resulting in hemoglobin SS (HbSS), hemoglobin SC (HbSC), and SCT cohorts and matched control cohorts.MAIN OUTCOME MEASURESRisk ratios (RRs) and 95% confidence intervals (CIs) of retinal vascular occlusion diagnosis, including central retinal artery occlusion (CRAO), branch retinal artery occlusion (BRAO), central retinal vein occlusion, branch retinal vein occlusion, and corneal dystrophy as a negative control, given SCD or SCT.RESULTSAfter propensity score matching, HbSS (n = 10 802; mean age ± standard deviation, 38.6 ± 20.6 years), HbSC (n = 4296, 34.3 ± 17.8 years), and SCT (n = 15 249, 39.8 ± 23.7 years) cohorts were compared with control cohorts (n = 10 802, 38.7 ± 20.7 years; n = 4296, 34.6 ± 18.0 years; n = 15 249, 39.9 ± 23.8 years, respectively). Patients with SCD (HbSS) had higher risk of developing any retinal vascular occlusion (RR, 2.33; 95% CI, 1.82-3.00), CRAO (RR, 2.71; 95% CI, 1.65-4.47), and BRAO (RR, 4.90; 95% CI, 2.48-9.67) than matched controls. Patients with HbSC disease had higher risk (RR, 3.14; 95% CI, 1.95-5.06) of developing any retinal vascular occlusion than matched controls without SCD. Patients with SCT did not have higher risk of developing retinal vascular occlusions (RR, 1.01; 95% CI, 0.81-1.26) than matched controls.CONCLUSIONSIn a retrospective cohort study, patients with HbSS SCD have an increased risk of developing retinal vascular occlusions, and more specifically CRAO and BRAO, compared with patients without SCD.FINANCIAL DISCLOSURE(S)Proprietary or commercial disclosure may be found in the Footnotes and Disclosures at the end of this article.

15 Oct 2024·Romanian Journal of Ophthalmology

Effects of intravitreal Bevacizumab (Avastin) monotherapy in central retinal vein occlusion in young subjects

Article

Author: Lobo, Sarita ; Vivekanand, Undrakonda ; Lobo, Geover Joslen

AimTo evaluate the efficacy of anti-angiogenic agent Bevacizumab in central retinal venous occlusion treatment.ObjectivesTo determine the efficacy of Bevacizumab and ophthalmological parameters such as best corrected visual acuity (BCVA) and central macular thickness (CMT) using optical coherence tomography (OCT) in central retinal venous occlusion in patients aged less than 30.MethodsThis is a prospective, interventional study, done on 25 eyes of 25 patients aged 30 years and below with central retinal venous occlusion, who received intravitreal Bevacizumab injections for three consecutive months. The mean change in best corrected visual acuity (BCVA), and central macular thickness (CMT) measured by optical coherence tomography were compared and correlated at baseline after 3 months and 6 months follow-up.ResultsThe mean best corrected visual acuity and the central macular thickness on OCT improved significantly from 1.08±0.29 and 454.80±114.5µm at baseline to 0.77±0.32 logMAR units and 339.7±82.5µm after 6 months follow up.ConclusionThe current study showed that intravitreal Bevacizumab at a dose of 1.25 mg and with strict control of systemic contributory parameters seemed to improve BCVA and CMT and macular edema measured at baseline to 3 months and 6 months follow-up after three consecutive monthly injections.

01 Sep 2024·Journal of Neuro-Ophthalmology

Papilledema and Combined Central Retinal Artery and Central Retinal Vein Occlusion as a Manifestation of Behçet Disease.

Letter

Author: Maheswaranathan, Mithu ; Schuman, Stefanie G ; Sengupta, Sweta ; Peters, Katherine S ; Gospe, Sidney M

Analysis

Perform a panoramic analysis of this field.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis

Central retinal vein occlusion - ischemic

Basic Info

Related

Analysis